Role of Vaccines in COPD Patients

Ji, Zichen; Jareño-Esteban, José Javier; Miguel‐Díez, Javier de

doi:10.1016/j.opresp.2022.100191

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to managing a patient's COPD with appropriate maintenance medication, other key factors to minimize risk of exacerbations include smoking cessation and vaccinations to prevent respiratory infections. 26,29,30 COPD is associated with an increased risk of cardiovascular disease and cardiovascular-related mortality. 31,32 Use of appropriate and effective maintenance therapy for COPD should reduce the frequency of exacerbations, 6 thereby reducing the need to use OCS that could further increase overall cardiovascular disease risk.…”

Section: Discussionmentioning

confidence: 99%

A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD

Tse,

Emmanuel,

Ariti

et al. 2023

COPD

View full text Add to dashboard Cite

Background: Oral corticosteroids (OCS) are often prescribed for chronic obstructive pulmonary disease (COPD) exacerbations. Methods: This observational, individually matched historical cohort study used electronic medical records from the UK Clinical Practice Research Datalink linked to English Hospital Episode Statistics (HES) to evaluate adverse outcomes in patients with COPD who used OCS (OCS cohort) and those not exposed to OCS (non-OCS cohort). Risk of 17 adverse outcomes was estimated using proportional hazard regression. Results: Of 323,722 patients, 106,775 (33.0%) had COPD-related OCS prescriptions. Of the 106,775 patients in the overall cohort, 58,955 had HES linkage and were eligible for inclusion in the OCS cohort. The individual matching process identified 53,299 pairs of patients to form the OCS and non-OCS cohorts. Median follow-up post-index was 6.9 years (OCS cohort) and 5.4 years (non-OCS cohort). Adjusted risk of multiple adverse outcomes was higher for the OCS cohort versus the non-OCS cohort, including osteoporosis with/without fractures (adjusted hazard ratio [aHR] 1.80; 95% confidence interval [CI] 1.70-1.92), type 2 diabetes mellitus (aHR 1.44; 95% CI 1.37-1.51), cardiovascular/cerebrovascular disease (aHR 1.26; 95% CI 1.21-1.30), and all-cause mortality (aHR 1.04; 95% CI 1.02-1.07). In the OCS cohort, risk of most adverse outcomes increased with increasing categorized cumulative OCS dose. For example, risk of cardiovascular/cerebrovascular disease was 34% higher in the 1.0-<2.5 g group versus the <0.5 g group (HR 1.34; 95% CI 1.26-1.42). Conclusion: Any OCS use was associated with higher risk of adverse outcomes in patients with COPD, with risk generally increasing with greater cumulative OCS dose.Plain Language Summary: Many patients with chronic obstructive pulmonary disease (COPD) have occasions when their symptoms suddenly worsen, called flare-ups or exacerbations. To treat flare-ups, doctors might prescribe a course of steroid tablets (oral corticosteroids or OCS for short). Doctors might also prescribe "rescue packs" containing OCS and antibiotics, to keep at home and start taking when needed.While OCS may speed up recovery from flare-ups, repeated use may have negative health effects. We studied effects of OCS use in patients with COPD, using anonymized electronic patient medical records in England. These databases are made available following a high-quality research proposal to research and ethics committees.Of 323,722 patients with COPD, around one-third received OCS for flare-ups. We studied 17 outcomes including important medical diagnoses and death. We grouped patients into 53,299 pairs so that every patient who used OCS matched a similar patient (eg, the same age and sex) who never used OCS. The patients were followed for an average of 6.9 years (used OCS) and 5.4 years (never used OCS).Most diagnoses, including diabetes, osteoporosis, cardiovascular/cerebrovascular disease, and death, were more likely in patients who used OCS than those who never used OCS. Patients using la...

show abstract

Section: Discussionmentioning

confidence: 99%

A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD

Tse,

Emmanuel,

Ariti

et al. 2023

COPD

View full text Add to dashboard Cite

show abstract

Plant-based therapeutics for chronic obstructive pulmonary diseases: Nanoformulation strategies to overcome delivery challenges

Kokkinis,

Singh,

Paudel

et al. 2024

Food Bioscience

View full text Add to dashboard Cite

Interplay between Lung Diseases and Viral Infections: A Comprehensive Review

Suri,

Pande,

Sahithi

et al. 2024

Microorganisms

View full text Add to dashboard Cite

The intricate relationship between chronic lung diseases and viral infections is a significant concern in respiratory medicine. We explore how pre-existing lung conditions, including chronic obstructive pulmonary disease, asthma, and interstitial lung diseases, influence susceptibility, severity, and outcomes of viral infections. We also examine how viral infections exacerbate and accelerate the progression of lung disease by disrupting immune responses and triggering inflammatory pathways. By summarizing current evidence, this review highlights the bidirectional nature of these interactions, where underlying lung diseasesincrease vulnerability to viral infections, while these infections, in turn, worsen the clinical course. This review underscores the importance of preventive measures, such as vaccination, early detection, and targeted therapies, to mitigate adverse outcomes in patients with chronic lung conditions. The insights provided aim to inform clinical strategies that can improve patient management and reduce the burden of chronic lung diseases exacerbated by viral infections.

show abstract

Role of Vaccines in COPD Patients

Cited by 3 publications

References 17 publications

A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD

A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD

Plant-based therapeutics for chronic obstructive pulmonary diseases: Nanoformulation strategies to overcome delivery challenges

Interplay between Lung Diseases and Viral Infections: A Comprehensive Review

Contact Info

Product

Resources

About